Literature DB >> 19845794

Clonal relationships between thyroid-stimulating hormone receptor-stimulating antibodies illustrate the effect of hypermutation on antibody function.

Carolyn J Padoa1, Sanne L Larsen, Christiane S Hampe, Jacqueline A Gilbert, Elif Dagdan, Laszlo Hegedus, Deborah Dunn-Walters, J Paul Banga.   

Abstract

Graves' disease is characterized by production of agonist antibodies to the thyroid-stimulating hormone receptor (TSHR), but knowledge of the genetic and somatic events leading to their aberrant production is limited. We describe the genetic analysis of two monoclonal antibodies (mAbs) with thyroid-stimulating activity (TSAb) obtained from a single mouse with experimental Graves' disease. The mAbs were class switched, but used the same rearrangement of immunoglobulin heavy chain, variable region (IGHV) and immunoglobulin light chain, variable region (IGLV) germline genes, implying a clonal relationship and derivation from a single precursor B-cell clone. The IGHV-region genes of the two mAbs underwent high degrees of somatic hypermutation by sharing numerous mutations before diverging, while the IGLV genes evolved separately. Interestingly, the mutations were present in both the complementarity-determining regions (CDRs) and the framework regions. The cloned IGHV and IGLV genes were confirmed to have TSAb properties in experiments in which they were expressed as recombinant Fabs (rFabs). In other experiments, we swapped the IGLV genes with IGHV genes by constructing chimeric rFabs and showed that the chimeras retained TSAb activities, confirming the close functional relatedness of the V-region genes. Importantly, the IGLV genes in chimeric rFabs had a dominant stimulatory effect at low concentrations, while the IGHV genes had a dominant effect at higher concentrations. Our findings demonstrate that, in experimentally immunized mice, multiple pathogenic antibodies to TSHR can arise from a single clone by a series of somatic mutations in the V-region genes and may give an insight into how such antibodies develop spontaneously in autoimmune Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845794      PMCID: PMC2814471          DOI: 10.1111/j.1365-2567.2009.03184.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

1.  Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes.

Authors:  G Vidarsson; J G van de Winkel; M A van Dijk
Journal:  J Immunol Methods       Date:  2001-03-01       Impact factor: 2.303

2.  Culture medium for enterobacteria.

Authors:  F C Neidhardt; P L Bloch; D F Smith
Journal:  J Bacteriol       Date:  1974-09       Impact factor: 3.490

3.  Immunochemical characterization of the thyroid-stimulating antibody (TSAb) of Graves' disease: evidence for restricted heterogeneity.

Authors:  M Zakarija
Journal:  J Clin Lab Immunol       Date:  1983-02

4.  Kappa/lambda immunoglobulin distribution in Graves' thyroid-stimulating antibodies. Simultaneous analysis of C lambda gene polymorphisms.

Authors:  R C Williams; N J Marshall; K Kilpatrick; J Montano; P M Brickell; M Goodall; P A Ealey; B Shine; A P Weetman; R K Craig
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

5.  Thyroid-stimulating monoclonal antibodies.

Authors:  Jane Sanders; Jennifer Jeffreys; Hilde Depraetere; Tonya Richards; Michele Evans; Angela Kiddie; Karen Brereton; Marleen Groenen; Yasuo Oda; Jadwiga Furmaniak; Bernard Rees Smith
Journal:  Thyroid       Date:  2002-12       Impact factor: 6.568

6.  Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function.

Authors:  J Sanders; J Jeffreys; H Depraetere; M Evans; T Richards; A Kiddie; K Brereton; L D K E Premawardhana; D Y Chirgadze; R Núñez Miguel; T L Blundell; J Furmaniak; B Rees Smith
Journal:  Thyroid       Date:  2004-08       Impact factor: 6.568

Review 7.  The environment and autoimmune thyroid diseases.

Authors:  Mark F Prummel; Thea Strieder; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-05       Impact factor: 6.664

8.  Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs.

Authors:  Carolyn J Padoa; J Paul Banga; Anne-Marie Madec; Manfred Ziegler; Michael Schlosser; Eva Ortqvist; Ingrid Kockum; Jerry Palmer; Olov Rolandsson; Katherine A Binder; Jefferson Foote; Dong Luo; Christiane S Hampe
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

Review 9.  Autoantibodies to the thyrotropin receptor.

Authors:  B Rees Smith; S M McLachlan; J Furmaniak
Journal:  Endocr Rev       Date:  1988-02       Impact factor: 19.871

Review 10.  Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.

Authors:  J Paul Banga; Claus H Nielsen; Jacqueline A Gilbert; Daniel El Fassi; Laszlo Hegedus
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.